GLP-1 Medications: Mechanism of Action, Clinical Differences, and Comparison
GLP-1–based therapies have transformed the treatment of type 2 diabetes mellitus (T2DM) and are increasingly used in chronic weight management. Originally developed to improve glycemic control, these medications now play a broader role in metabolic disease due to their favorable effects on body weight, cardiovascular risk, and low intrinsic risk of hypoglycemia.
The GLP-1 medication class includes several GLP-1 receptor agonists, such as dulaglutide, liraglutide, and semaglutide, as well as newer dual incretin therapies like tirzepatide. While these drugs share a common biological pathway, important differences exist in duration of action, dosing frequency, potency, and clinical outcomes, making individualized treatment selection essential.
Mechanism of Action of GLP-1 Medications
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by intestinal L-cells in response to food intake. In physiological conditions, GLP-1 enhances insulin secretion but is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4), resulting in a very short half-life.
GLP-1 receptor agonists are designed to resist DPP-4 degradation and prolong incretin activity. According to Katzung, their glucose-lowering effects occur through several coordinated mechanisms:
- Stimulation of insulin secretion in a glucose-dependent manner
- Suppression of glucagon release, reducing hepatic glucose production
- Delayed gastric emptying, lowering postprandial glucose excursions
- Central appetite suppression, leading to reduced caloric intake and weight loss
Because insulin release depends on ambient glucose levels, GLP-1 medications carry a low risk of hypoglycemia when used alone.
Dual Incretin Therapy: Tirzepatide
Tirzepatide differs from traditional GLP-1 receptor agonists by activating both:
- GLP-1 receptors
- Glucose-dependent insulinotropic polypeptide (GIP) receptors
This dual mechanism results in enhanced insulin secretion, greater HbA1c reductions, and more pronounced weight loss compared with GLP-1 receptor agonists alone.
GLP-1 Medications: Individual Overview
Exenatide
Brand: Byetta®
Manufacturer: AstraZeneca
Exenatide is a short-acting GLP-1 receptor agonist derived from exendin-4. It was the first agent in this class approved for clinical use.
- Dosing: Twice-daily injection
- Strong effect on postprandial glucose
- Resistant to DPP-4 degradation
Common adverse effects: nausea, vomiting, diarrhea
Exenatide Extended-Release
Brand: Bydureon BCise®
Manufacturer: AstraZeneca
This formulation uses biodegradable microspheres to allow continuous drug release.
- Dosing: Once-weekly injection
- Improved fasting glucose control
Notable adverse effect: injection-site nodules
Liraglutide
Brands: Victoza® (diabetes), Saxenda® (obesity)
Manufacturer: Novo Nordisk
Liraglutide is a long-acting GLP-1 analog modified with a fatty acid side chain that prolongs its half-life.
- Dosing: Once-daily injection
- Demonstrated cardiovascular benefit
- Approved for chronic weight management
Lixisenatide
Brand: Adlyxin®
Manufacturer: Sanofi
Lixisenatide is a short-acting GLP-1 receptor agonist with a pronounced effect on postprandial glucose levels.
- Dosing: Once-daily injection
- Strong gastric emptying delay
Dulaglutide
Brand: Trulicity®
Manufacturer: Eli Lilly and Company
Dulaglutide is a GLP-1 analog fused to an IgG4 Fc fragment, which slows renal clearance and enzymatic degradation.
- Dosing: Once-weekly injection
- Proven cardiovascular benefit
- Simplified dosing improves adherence
Semaglutide (Injectable)
Brands: Ozempic® (diabetes), Wegovy® (obesity)
Manufacturer: Novo Nordisk
Semaglutide is a highly potent long-acting GLP-1 receptor agonist.
- Dosing: Once-weekly injection
- Significant HbA1c and weight reduction
- Strong central appetite suppression
Semaglutide (Oral)
Brand: Rybelsus®
Manufacturer: Novo Nordisk
Oral semaglutide uses the absorption enhancer SNAC to enable gastric uptake.
- Dosing: Once-daily oral tablet
- Requires strict administration conditions
- Similar efficacy to injectable GLP-1 agents when taken correctly
Tirzepatide
Brands: Mounjaro® (diabetes), Zepbound® (obesity)
Manufacturer: Eli Lilly and Company
Tirzepatide is the first dual GIP/GLP-1 receptor agonist approved for clinical use.
- Dosing: Once-weekly injection
- Produces the greatest reductions in HbA1c and body weight
- Represents a new generation of incretin-based therapy
Comparison Table: GLP-1 Medications
| Medication | Brand | Dosing | Type | Weight Loss | CV Benefit |
|---|---|---|---|---|---|
| Exenatide | Byetta | 2× daily | GLP-1 | Mild | No |
| Exenatide ER | Bydureon | Weekly | GLP-1 | Moderate | No |
| Liraglutide | Victoza / Saxenda | Daily | GLP-1 | Moderate–High | Yes |
| Lixisenatide | Adlyxin | Daily | GLP-1 | Mild | Neutral |
| Dulaglutide | Trulicity | Weekly | GLP-1 | Moderate | Yes |
| Semaglutide inj. | Ozempic / Wegovy | Weekly | GLP-1 | High | Yes |
| Semaglutide oral | Rybelsus | Daily (oral) | GLP-1 | Moderate | Pending |
| Tirzepatide | Mounjaro / Zepbound | Weekly | GIP + GLP-1 | Very High | Emerging |
Adverse Effects and Safety Considerations
The most common adverse effects of GLP-1 medications are gastrointestinal, including nausea, vomiting, diarrhea, and abdominal discomfort. These effects are dose-dependent and often improve with gradual titration.
Less common but clinically relevant risks include:
- Pancreatitis (rare)
- Gallbladder disease associated with rapid weight loss
- Dehydration-related kidney injury
GLP-1 medications are contraindicated in patients with medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2), based on rodent studies cited in prescribing information.
Conclusion
GLP-1 receptor agonists and dual incretin therapies represent a cornerstone of modern metabolic disease management. By targeting multiple pathways involved in glucose regulation and appetite control, these medications provide benefits that extend beyond glycemic control alone. Understanding the pharmacologic differences between individual agents allows clinicians to tailor therapy based on patient-specific goals, tolerability, and cardiovascular risk.
References
- Katzung BG, Trevor AJ. Basic & Clinical Pharmacology, latest edition
- Katzung & Trevor’s Pharmacology Examination & Board Review
- Prescribing information: Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca
Last Updated: December 2025
We’ve prepared an up-to-date comparison of leading GLP-1 weight-loss providers, reviewed for safety, availability, and care model
All GLP-1 medications require a prescription and medical supervision.
Information is for educational purposes only and is not medical advice.
DISCLAIMER